Text · Comparison of two versions

Changes from plenary report to adopted text

A-9-2024-0140 → TA-9-2024-0220

From: A-9-2024-0140 Plenary report of 21 Mar 2024
To: TA-9-2024-0220 Adopted text of 10 Apr 2024
Changes: Not comparable
Paragraphs: +3 331 added · −358 removed · 2 changed

More facts (2)

Title (from): on the proposal for a directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC
Title (to): Union code relating to medicinal products for human use

Title (from): on the proposal for a directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC
Title (to): Union code relating to medicinal products for human use

These two texts have too little in common to be compared paragraph by paragraph (under 15 % of their paragraphs match): they are different documents rather than versions of one — for example a group’s motion and the joint text that was adopted.

Every difference

The full paragraph comparison, packaging included; long runs of unchanged paragraphs are folded. One part of the text per page.

Part 63 of 63: Paragraphs 3697–3705

Added(a) take into account the particular condition of certain categories of users (children, pregnant or breastfeeding women, older adults, persons with specific pathological conditions and persons with disabilities);

Added(b) mention, if appropriate, possible effects on the ability to drive vehicles or to operate machinery;

Added(c) list those excipients the knowledge of which is important for the safe and effective use of the medicinal product and that are included in the detailed guidance referred to in Article 77.

AddedThe package leaflet may also contain information on the importance of therapeutic adherence and available support for adherence in the Member State. [Am. 338]

AddedAnnex VII

AddedAREAS FOR ADAPTED FRAMEWORKS REFERRED TO IN ARTICLE 28

AddedPhage-containing medicinal products, in cases where the medicinal product has a variable composition depending on the specific clinical context.

AddedAnnex VIII

AddedCORRELATION TABLE

Sources & citation

Where the facts on this page come from, and how to cite it.

Permalink: https://news.eu-parl.st-solutions.dev/texts/A-9-2024-0140/compare/TA-9-2024-0220?all=1&part=63
Data source: European Parliament Open Data
Licensed CC BY 4.0.
Retrieved: 29 September 2026

Cite as

European Parliament (2024). “Changes between A-9-2024-0140 and TA-9-2024-0220”. Text, 10 April 2024. from A-9-2024-0140, to TA-9-2024-0220. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/texts/A-9-2024-0140/compare/TA-9-2024-0220?all=1&part=63 (retrieved 29 September 2026). Data: European Parliament Open Data, https://data.europarl.europa.eu/ (CC BY 4.0).

BibTeX

@misc{epw-text-2024-04-10,
  author = {{European Parliament}},
  title = {{Changes between A-9-2024-0140 and TA-9-2024-0220}},
  year = {2024},
  date = {2024-04-10},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/texts/A-9-2024-0140/compare/TA-9-2024-0220?all=1&part=63}},
  url = {https://news.eu-parl.st-solutions.dev/texts/A-9-2024-0140/compare/TA-9-2024-0220?all=1&part=63},
  urldate = {2026-09-29},
  publisher = {EU Parl Watch Research},
  note = {Text. from A-9-2024-0140, to TA-9-2024-0220. Data: European Parliament Open Data (CC BY 4.0)}
}